Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 37 - 48 of 430
General Hepatology
Quiz: A 39-year-old man with ulcerative colitis for 10 years and treated with 5-ASA has also primary sclerosing cholangitis (PSC) for the last 5 years

Quiz: A 39-year-old man with ulcerative colitis for 10 years and treated with 5-ASA has also primary sclerosing cholangitis (P...

Quiz
View
Cirrhosis & Complications
EASL Studio Podcast S6 E3: How to stop recurrent bleeding due to small-intestinal angiodysplasia?

EASL Studio Podcast S6 E3: How to stop recurrent bleeding due to small-intestinal angiodysplasia?

Podcasts
View

EASL Studio S6 E2: Why do we need HBV functional cure?

Description

In this episode, the panellists evaluate past efforts, current trials, and the evolving landscape of HBV cure research. They also weigh the patient-friendliness of these strategies, exploring potential pathways to a cure. How will the landscape of trials and research methodologies evolve in the future to facilitate this quest?

Faculty

  • Ahmed Elsharkawy (Moderator)
  • Markus Cornberg (Faculty)
  • Dickens Theodore (GSK Representative)
  • Su Wang (Faculty)

This EASL Studio is supported by GSK.

Related episodes:

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership
Off
General Hepatology

State-of-the-Art: Improving liver health in Europe: the EASL-Lancet Liver Commission initiative (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity
On-demand Webinar: Steatotic liver disease – the missing piece in the NCD puzzle

On-demand Webinar: Steatotic liver disease – the missing piece in the NCD puzzle

On-demand Webinars
View
Viral Hepatitis
EASL Studio Podcast S6 E2: Why do we need HBV functional cure?

EASL Studio Podcast S6 E2: Why do we need HBV functional cure?

Podcasts
View
Metabolism, Alcohol & Toxicity
Quiz: In alcohol-related liver cirrhosis

Quiz: In alcohol-related liver cirrhosis

Quiz
View

EASL Studio S6 E1: Do we solve MASLD by treating obesity?

Description

Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.

Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!

Faculty

  • Sven Francque (Moderator)
  • Willem Pieter Brouwer (Faculty)
  • Cyrielle Caussy (Faculty)
  • Dimitris Papamargaritis (Faculty)

This episode is scheduled following the United Kingdom’s National Obesity Awareness Week.

Related episodes:

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership
Off
Metabolism, Alcohol & Toxicity
EASL Studio Podcast S6 E1: Do we solve MASLD by treating obesity?

EASL Studio Podcast S6 E1: Do we solve MASLD by treating obesity?

Podcasts
View

EASL Policy Dialogues S2 E10: Technology and misinformation: The importance of digital health literacy

Description

The spread of misinformation may be as harmful to the health of Europeans as disease itself. Misinformation, particularly circulated through social media and on the internet, impedes and undermines the efficacy of public health responses.

This episode explores the concept of digital health literacy, its underestimation during the Covid-19 pandemic, and lessons learned in the fight against the infodemic. Prof. Mookerjee, expert in health education, presents key issues, challenges, and areas of action in the field of digital health literacy. George Kalamitsis, a patient advocate, provides his insights on strategies to improve digital health literacy at a community level.

 

Speakers

 
raj

Prof. Mookerjee is professor of translational hepatology at UCL and honorary consultant in hepatology at the Royal Free hospital. He is also Jens Skou Professor of Hepatology in Aarhus University, Denmark, and the secretary-elect for the British Association for Study of the Liver. He serves on the steering committee for the European Foundation for the Study of Chronic Liver Failure and the European Association for Study of the Liver’s education committee.

george

George Kalamitsis, is founding member and Chair of Board of Hellenic Liver Patients Association "Prometheus", since 2012. He focuses daily on providing support to people living with Viral Hepatitis and Other Liver Diseases, on advocating for their rights, as well as on providing factual information related to hepatitis. He has worked extensively with all stakeholders in Greece, focusing on patients benefits and maintains communication channels with organizations and stakeholders, on a European and International level.

Log in to post comments
EASL Membership
Off
Cirrhosis & Complications
Quiz: A 58-year-old woman with a background of obesity and type II Diabetes Mellitus, and diagnosis of steatotic liver disease-induced cirrhosis

Quiz: A 58-year-old woman with a background of obesity and type II Diabetes Mellitus, and diagnosis of steatotic liver disease...

Quiz
View

EASL Studio S4 E12: NAFLD and NASH – moving beyond the liver biopsy – where are we now?

Description

Liver biopsy has long been the gold standard for diagnosing NAFLD and NASH. However, it is an invasive  procedure that may not always be necessary. This episode of EASL Studio explored methods for screening, staging, and monitoring disease progression.

Faculty

  • Prof. Philip Newsome (Moderator)
  • Prof. Laurent Castera (Faculty)
  • Prof. Maja Thiele (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

 

Log in to post comments